2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, D. Articles by Grantham, J. J. Search for Related Content PubMed PubMed Citation Articles by Zheng, D. Articles by Grantham, J. J.

Urinary Excretion of Monocyte Chemoattractant Protein-1 in Autosomal Dominant Polycystic Kidney Disease

Kidney Institute, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas

Correspondence to Dr. Jared J. Grantham, Kidney Institute, Kansas University Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160. Phone: 913-588-6074; Fax: 913-588-7606;

ABSTRACT. Autosomal dominant polycystic kidney disease (ADPKD) progresses to renal insufficiency in >50% of patients and is characterized by interstitial inflammation and fibrosis in the end stage. In a rat model of ADPKD, monocytes accumulate within the renal interstitium in association with increased levels of monocyte chemoattractant protein-1 (MCP-1) in cyst mural cells and increased excretion of this chemokine into the urine. For determining the extent to which this chemokine is abnormally expressed in patients with ADPKD, a cross-section study was performed of MCP-1 in urine, serum, and cyst fluid and MCP-1 production by mural epithelial cells cultured from the cysts of human patients with ADPKD. Upper boundaries for urinary MCP-1 excretion (>263 pg/mg creatinine) and serum creatinine concentration (>1.5 mg/dl) determined in 19 normal individuals were used to sort 55 ADPKD patients into three groups. In group 1 (n = 13), urine MCP-1 excretion (136 ± 14 pg/mg creatinine) was not different from normal volunteers (152 ± 16 pg/mg); serum creatinine levels and urine total protein excretion were normal as well. In group 2 (n = 27), urine MCP-1 excretion was increased (525 ± 39 pg/mg creatinine), but serum creatinine levels and urine protein excretion were not different from normal. In group 3 (n = 15), urine MCP-1 excretion increased further (1221 ± 171 pg/mg), serum creatinine levels increased to 4.3 ± 0.8 mg/dl, and urine protein excretion rose to 0.64 ± 0.28 mg/mg creatinine. Serum MCP-1 levels of ADPKD patients (84 ± 9.9 pg/ml; n = 15) did not differ from normal. Levels of MCP-1 much higher than in serum or urine were found in cyst fluids obtained from nephrectomy specimens (range, 767 to 40,860 pg/ml; mean, 6434 ± 841 pg/ml; n = 73). Polarized, confluent cultures of ADPKD cyst epithelial cells secreted MCP-1 into the apical fluid to levels eightfold greater than in the basolateral medium. Similar results were obtained with tubule epithelial cells cultured from normal human renal cortex. On the basis of these results, it is concluded that urinary excretion of MCP-1 is increased in the majority of adult patients with ADPKD and that the source of some of this chemokine may be the mural epithelium of cysts. Furthermore, it seemed that urinary MCP-1 excretion may have increased in these ADPKD patients before appreciable increases in serum creatinine concentration or urine protein excretion were detected. It is reasonable to include urine MCP-1 excretion among candidate surrogate markers in controlled, longitudinal studies of ADPKD. E-mail: jgrantha@kumc.edu

This article has been cited by other articles:

				A. P. Bastos, K. Piontek, A. M. Silva, D. Martini, L. F. Menezes, J. M. Fonseca, I. I. Fonseca, G. G. Germino, and L. F. Onuchic Pkd1 Haploinsufficiency Increases Renal Damage and Induces Microcyst Formation following Ischemia/Reperfusion J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2389 - 2402. [Abstract] [Full Text] [PDF]

				P. J. Azurmendi, A. R. Fraga, F. M. Galan, C. Kotliar, E. E. Arrizurieta, M. G. Valdez, P. J. Forcada, J. S. S. Stefan, and R. S. Martin Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2458 - 2463. [Abstract] [Full Text] [PDF]

				D. P. Wallace, M. T. Quante, G. A. Reif, E. Nivens, F. Ahmed, S. J. Hempson, G. Blanco, and T. Yamaguchi Periostin induces proliferation of human autosomal dominant polycystic kidney cells through {alpha}V-integrin receptor Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1463 - F1471. [Abstract] [Full Text] [PDF]

				J. J. Grantham Autosomal Dominant Polycystic Kidney Disease N. Engl. J. Med., October 2, 2008; 359(14): 1477 - 1485. [Full Text] [PDF]

				J. J. Grantham, A. B. Chapman, and V. E. Torres Volume Progression in Autosomal Dominant Polycystic Kidney Disease: The Major Factor Determining Clinical Outcomes Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 148 - 157. [Abstract] [Full Text] [PDF]

				I. A. Hauser, S. Spiegler, E. Kiss, S. Gauer, O. Sichler, E. H. Scheuermann, H. Ackermann, J. M. Pfeilschifter, H. Geiger, H.-J. Grone, et al. Prediction of Acute Renal Allograft Rejection by Urinary Monokine Induced by IFN-{gamma} (MIG) J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1849 - 1858. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673